Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Cancer Immunology, Immunotherapy : CII|October 31, 2022
Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysisKathryn Owen, Ramy Ghaly, Kyrillus S Shohdy, et al.
Cancer Nursing|March 19, 2025
The Barriers and Enablers to Participation in Oncology Clinical Trials for Ethnically Diverse Communities: A Qualitative Systematic Review Using MetaethnographyLorraine Turner, Sally Taylor, Ashleigh Ward, et al.
Current Opinion in Molecular Therapeutics|March 1, 2005
Engineering T-cells with antibody-based chimeric receptors for effective cancer therapyFiona Thistlethwaite, Wasat Mansoor, David E Gilham, et al.
Pharmacoeconomics|March 11, 2023
Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic ReviewSean P Gavan, Stuart J Wright, Fiona Thistlethwaite, et al.
BMC Cancer|March 28, 2025
A single centre experience of patients with rare cancers referred for early phase clinical trialsAngelos Angelakas, Natalie Cook, Donna M Graham, et al.
Oncoimmunology|February 21, 2025
Patient-specific HLA-I subtypes predict response to immune checkpoint blockadeKyrillus S Shohdy, Jack Atherton, Jessica Longland, et al.
British Journal of Cancer|February 18, 2026
Tumour-infiltrating lymphocyte therapy in melanoma: ready for prime time?Rachel Woodford, Paul Lorigan, Deemesh Oudit, et al.
Therapeutic Advances in Medical Oncology|June 17, 2026
Cytokine release syndrome in solid tumours: mechanism-based therapeutic strategies for prevention and managementFederico Monaca, Rachel Woodford, Kroopa Joshi, et al.
World Journal of Gastroenterology|April 19, 2014
Immunohistochemical assessment of NY-ESO-1 expression in esophageal adenocarcinoma resection specimensStephen J Hayes, Keng Ngee Hng, Peter Clark, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 15, 2010
High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancerAlaaeldin Shablak, Kanwal Sikand, Jonathan H Shanks, et al.
Pageof 5